Franklin Genomic Advancements ETF
Name
As of 09/05/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
5.5%
1 yr return
6.5%
3 Yr Avg Return
-17.8%
5 Yr Avg Return
N/A
Net Assets
$9.65 M
Holdings in Top 10
45.9%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 0.50%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 61.43%
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Exchange Traded Fund
Name
As of 09/05/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
HELX - Profile
Distributions
- YTD Total Return 5.5%
- 3 Yr Annualized Total Return -17.8%
- 5 Yr Annualized Total Return N/A
- Capital Gain Distribution Frequency N/A
- Net Income Ratio -0.32%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameFranklin Genomic Advancements ETF
-
Fund Family NameFranklin Templeton Group of Funds
-
Inception DateFeb 27, 2020
-
Shares Outstanding349986
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerJoyce Lin
Fund Description
Under normal market conditions, the Fund invests at least 80% of its net assets in equity securities of companies that are relevant to the Fund’s investment theme of genomic advancements. The Fund invests predominantly in common stock.
Companies relevant to the Fund’s investment theme of genomic advancements are those that the investment manager believes are substantially focused on and/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by offering new products or services that rely on genetic engineering, gene therapy, genome analysis, DNA sequencing, synthesis or instrumentation. These companies may include those that research, develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics, molecular medicine and diagnostics, pharmaceuticals and agricultural applications of genomics, and related equipment, techniques and processes.
In pursuing the Fund’s investment theme, the investment manager may invest in companies in any economic sector or of any market capitalization and may invest in companies both inside and outside of the United States, including those in developing or emerging markets. Although the Fund may invest across economic sectors, the Fund concentrates its investments in health care related industries. The Fund is a “non-diversified” fund, which means it generally invests a greater proportion of its assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund.
In selecting companies that the investment manager believes are relevant to the Fund’s investment theme of genomic advancements, the investment manager seeks to identify, using its own fundamental, “bottom-up” research and analysis, companies positioned to capitalize on disruptive innovation in or that are enabling the further development of the genomic advancements theme in the markets in which they operate. The investment manager’s internal research and analysis leverages insights from diverse sources, including external research, to develop and refine its investment theme and identify and take advantage of trends that have ramifications for individual companies or entire industries. The investment manager also evaluates market segments, products, services and business models positioned to benefit significantly from advancements in genomics relative to broad
securities markets, and seeks to identify the primary beneficiaries of new trends or developments in genomics to select investments for the Fund.
The investment manager may seek to sell a security if: (i) the security reaches its valuation target; (ii) the security reaches its position size limit in the Fund’s portfolio; (iii) the security’s fundamentals deteriorate; (iv) there are adverse policy changes that could affect the security’s outlook; or (v) better investment opportunities become available.
HELX - Performance
Return Ranking - Trailing
Period | HELX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | 5.5% | -23.9% | 32.0% | 87.58% |
1 Yr | 6.5% | -22.0% | 36.8% | 88.82% |
3 Yr | -17.8%* | -34.0% | 13.6% | 96.10% |
5 Yr | N/A* | -4.8% | 16.8% | 49.64% |
10 Yr | N/A* | -0.4% | 13.5% | 71.43% |
* Annualized
Return Ranking - Calendar
Period | HELX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | 1.1% | -12.6% | 19.0% | 63.35% |
2022 | -37.9% | -53.9% | 3.2% | 97.40% |
2021 | 9.5% | -39.6% | 24.2% | 22.08% |
2020 | N/A | -13.6% | 178.2% | N/A |
2019 | N/A | 3.8% | 63.8% | N/A |
Total Return Ranking - Trailing
Period | HELX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | 5.5% | -23.9% | 32.0% | 87.58% |
1 Yr | 6.5% | -22.0% | 36.8% | 88.82% |
3 Yr | -17.8%* | -34.0% | 13.6% | 96.10% |
5 Yr | N/A* | -4.8% | 16.8% | N/A |
10 Yr | N/A* | -0.4% | 13.5% | N/A |
* Annualized
Total Return Ranking - Calendar
Period | HELX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | 1.1% | -12.6% | 19.0% | 80.12% |
2022 | -37.9% | -53.9% | 3.7% | 97.40% |
2021 | 9.8% | -33.9% | 26.0% | 49.35% |
2020 | N/A | -0.7% | 180.6% | N/A |
2019 | N/A | 4.6% | 63.8% | N/A |
HELX - Holdings
Concentration Analysis
HELX | Category Low | Category High | HELX % Rank | |
---|---|---|---|---|
Net Assets | 9.65 M | 6.83 M | 47.2 B | 89.44% |
Number of Holdings | 59 | 26 | 414 | 75.78% |
Net Assets in Top 10 | 4.37 M | 3.14 M | 22.1 B | 90.06% |
Weighting of Top 10 | 45.94% | 18.9% | 79.7% | 48.45% |
Top 10 Holdings
- Medpace Holdings Inc 7.21%
- Vertex Pharmaceuticals Inc 5.53%
- Regeneron Pharmaceuticals Inc 5.35%
- Eli Lilly Co 4.98%
- Danaher Corp 4.91%
- Thermo Fisher Scientific Inc 4.64%
- Krystal Biotech Inc 4.48%
- Natera Inc 3.41%
- AstraZeneca PLC 2.72%
- Samsung Biologics Co Ltd 2.72%
Asset Allocation
Weighting | Return Low | Return High | HELX % Rank | |
---|---|---|---|---|
Stocks | 97.65% | 87.34% | 106.13% | 68.32% |
Preferred Stocks | 1.98% | 0.00% | 7.86% | 14.91% |
Cash | 0.38% | 0.00% | 32.72% | 77.02% |
Other | 0.00% | -22.99% | 23.61% | 70.19% |
Convertible Bonds | 0.00% | 0.00% | 0.37% | 64.74% |
Bonds | 0.00% | 0.00% | 12.39% | 68.94% |
Stock Sector Breakdown
Weighting | Return Low | Return High | HELX % Rank | |
---|---|---|---|---|
Healthcare | 89.08% | 59.26% | 100.00% | 98.72% |
Basic Materials | 7.16% | 0.00% | 7.16% | 0.64% |
Real Estate | 2.34% | 0.00% | 5.89% | 3.85% |
Technology | 1.42% | 0.00% | 22.69% | 2.56% |
Utilities | 0.00% | 0.00% | 0.00% | 62.18% |
Industrials | 0.00% | 0.00% | 7.02% | 65.38% |
Financial Services | 0.00% | 0.00% | 1.60% | 69.23% |
Energy | 0.00% | 0.00% | 0.00% | 62.18% |
Communication Services | 0.00% | 0.00% | 9.11% | 62.82% |
Consumer Defense | 0.00% | 0.00% | 25.73% | 67.95% |
Consumer Cyclical | 0.00% | 0.00% | 1.92% | 64.10% |
Stock Geographic Breakdown
Weighting | Return Low | Return High | HELX % Rank | |
---|---|---|---|---|
US | 93.50% | 66.06% | 104.41% | 52.80% |
Non US | 4.15% | 0.00% | 28.87% | 41.61% |
HELX - Expenses
Operational Fees
HELX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Expense Ratio | 0.50% | 0.08% | 4.48% | 86.34% |
Management Fee | 0.50% | 0.03% | 1.25% | 16.15% |
12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
HELX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Front Load | N/A | 3.50% | 5.75% | N/A |
Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
HELX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
HELX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Turnover | 61.43% | 0.00% | 238.00% | 75.18% |
HELX - Distributions
Dividend Yield Analysis
HELX | Category Low | Category High | HELX % Rank | |
---|---|---|---|---|
Dividend Yield | 0.00% | 0.00% | 6.24% | 76.40% |
Dividend Distribution Analysis
HELX | Category Low | Category High | Category Mod | |
---|---|---|---|---|
Dividend Distribution Frequency | Annual | Annual | SemiAnnual | Annual |
Net Income Ratio Analysis
HELX | Category Low | Category High | HELX % Rank | |
---|---|---|---|---|
Net Income Ratio | -0.32% | -2.54% | 1.85% | 57.79% |
Capital Gain Distribution Analysis
HELX | Category Low | Category High | Capital Mode | |
---|---|---|---|---|
Capital Gain Distribution Frequency | Annually | Semi-Annually | Annually |
Distributions History
Date | Amount | Type |
---|---|---|
Dec 30, 2021 | $0.004 | OrdinaryDividend |
Dec 13, 2021 | $0.114 | OrdinaryDividend |
Dec 14, 2020 | $0.052 | OrdinaryDividend |
HELX - Fund Manager Analysis
Managers
Joyce Lin
Start Date
Tenure
Tenure Rank
Feb 25, 2020
2.26
2.3%
Ms. Lin has been a portfolio manager of Franklin Tenmpleton, providing research and advice on the purchases and sales of individual securities, and portfolio risk assessment. She joined Franklin Templeton in 2014. Prior to joining Franklin Templeton in 2014, Ms. Lin was a research associate at Cooke & Bieler, a value based investment management firm.
Matthew Moberg
Start Date
Tenure
Tenure Rank
Feb 25, 2020
2.26
2.3%
Moberg is a Vice President, Portfolio Manager and Research Analyst of Franklin Advisers, Inc. He provides research and advice on the purchases and sales of individual securities, and portfolio risk assessment. He joined Franklin Templeton Investments in 1998. Moberg holds the Certified Public Accountant designation. Mr. Moberg earned his B.A. in history from Washington and Lee University and an M.B.A. with distinction from the University of Michigan.
Tenure Analysis
Category Low | Category High | Category Average | Category Mode |
---|---|---|---|
0.02 | 24.72 | 7.87 | 0.25 |